Neuropacs De Novo: First FDA-Authorized AI Pathway for Chronic Neurodegenerative Disease Differentiation
Event Date: April 3, 2026 (FDA decision) | April 7, 2026 (public announcement)
Marketstrat® · Markintel Market Signals
Neuropacs De Novo: First FDA-Authorized AI Pathway for Chronic Neurodegenerative Disease Differentiation
Published: April 16, 2026Sector: MedTech & Digital HealthFocus: Neurological Imaging AI
FDA grants De Novo classification to neuropacs™ (April 3, 2026)
Creates a new device category — “Parkinsonian syndrome diagnostic aid” (21 CFR 882.2000, product code SHO). First FDA-authorized AI tool for differentiating Parkinson’s disease from atypical parkinsonism using diffusion MRI.
0.96
AUROC
PD vs. atypical parkinsonism
0.98
AUROC
MSA vs. PSP
93.9%
Accuracy
Autopsy-confirmed (46 of 49)
The FDA has opened a new regulatory pathway for chronic neurodegenerative disease AI. Neuro AI has concentrated almost entirely in acute indications (stroke, ICH). SHO establishes that chronic-disease neurodegenerative AI can clear the FDA bar — and creates a 510(k) predicate for competitors that will follow.
Regulatory facts
De Novo Number
DEN240071
Product Code
SHO · Class II · 21 CFR 882.2000
510(k) Predicate Status
Not Exempt — open to competitors
PCCP (Change Control)
Not authorized — updates need new filing
Pivotal Evidence
JAMA Neurology · n=249 · 21 centers
Capital Status
$1M seed (Jan 2026) · No Series A
Neuro AI has clustered in the acute/neurovascular quadrants. Neuropacs is alone in the chronic/narrow quadrant as of April 2026 — the structural gap the De Novo opened. Hover a company for details.
Strategic read: The 510(k) “Not Exempt” status means competitors can now cite SHO as a predicate on the shorter 510(k) pathway. GE HealthCare is the most concrete near-term fast-follower threat — its September 2025 acquisition of icometrix (closed Q1 2026) combines MRI hardware distribution, brain MRI 510(k) portfolio, and active PD biomarker research into a single platform.
The De Novo matters differently to different constituencies. Select a stakeholder to see the first-order implication.
Four high-conviction inflection points will determine whether Neuropacs captures the category it just created — and whether the 510(k) predicate window stays open long enough to matter.
▲ Catalysts (Upside)
1First pharma / CRO contractHighest-conviction near-term commercial channel. Disease-modifying PD trials need diagnostic precision at enrollment.
2Series A close ($10–20M)Commercialization pace is capital-constrained. Absence of a round within 12 months raises questions.
3FDA decision summary publicationReveals the evidence bar and competitive framing for incoming SHO 510(k) filings.
4Academic MDC pilot installationsUPenn, Hopkins, UCSF, Mayo — validation beyond the 21 pivotal trial sites.
▼ Risks (Downside)
1NGS LCD DL40332 finalizes as non-coverageProposed Medicare non-coverage for CPT 0865T/0866T across 10 states; pending after Mar 8 comment close.
2Parallel non-coverage from other MACsNoridian, Palmetto, Novitas, or WPS following NGS would structurally block brain MRI AI reimbursement.
3Fast-follower 510(k) filing via SHO predicateGE HealthCare (via icometrix) is the most concrete threat; Cortechs.ai is the other plausible fast-follower. Window: 6–12 months.
